Journal
TRENDS IN PHARMACOLOGICAL SCIENCES
Volume 37, Issue 3, Pages 220-230Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2015.11.004
Keywords
-
Categories
Funding
- NIH [CA178844, CA187592, CA180723]
Ask authors/readers for more resources
The tumor-killing properties of T cells provide tremendous opportunities to treat cancer. Adoptive T cell therapies have begun to harness this potential by endowing a functionally diverse repertoire of T cells with genetically modified, tumor-specific recognition receptors. Normally, this antigen recognition function is mediated by an alpha beta T cell receptor (TCR), but the dominant therapeutic forms currently in development are synthetic constructs called chimeric antigen receptors (CARs). While CAR-based adoptive cell therapies are already showing great promise, their basic mechanistic properties have been studied in less detail compared with those of alpha beta TCRs. In this review, we compare and contrast various features of TCRs versus CARs, with a goal of highlighting issues that need to be addressed to fully exploit the therapeutic potential of both.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available